NCT05447078View on ClinicalTrials.gov

Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

PHASE3RecruitingINTERVENTIONAL
Enrollment

472

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

June 30, 2026

Conditions
Healthy Volunteers
Interventions
DRUG

Immulina TM

Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.

DIETARY_SUPPLEMENT

Placebo

Placebo is inert powder in cellulose capsule that appears identical to Immulina TM capsules.

Trial Locations (1)

39216

RECRUITING

University of Mississippi Medical Center, Jackson

All Listed Sponsors
collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

lead

University of Mississippi Medical Center

OTHER